Meningococcal Vaccine Market Global Opportunity Analysis, Size, Share, Growth, Scope, Trends, Covid-19 Analysis, Top Companies Details and Industry Forecast, 2020–2026

According to the report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/330

Increase in outbreaks of meningococcal disease, surge in immunization programs across the globe, and rise in research and development for vaccine technology propel the growth of the global meningococcal vaccine market. However, longer timelines required for vaccine production and high cost associated with the development of vaccines impede the market growth. On the other hand, rise in healthcare spending, increase in research and development for meningococcal vaccines, and growing opportunities in the emerging markets offer lucrative opportunities to the market players.

Covid-19 scenario

Due to lockdown, immunization programs will come to a halt and program schedules will be changed in various countries.
Research and development activities for vaccine technology will be limited, as researchers need to stay at home during the lockdown.
Meningococcal vaccine is used as a placebo effect in the Covid-19 vaccine trial conducted at the University of Oxford.
Based on vaccine type, the conjugate segment accounted for the largest market share with nearly half of the total share in 2018, and is estimated to maintain its lead position throughout the forecast period. In addition, the segment is expected to register the fastest CAGR of 10.2% from 2019 to 2026.

Based on region, North America accounted for the highest share, holding nearly half of the total share in 2018, and is estimated to maintain its dominant share during the forecast period. On the other hand, the Asia-Pacific region is also anticipated to manifest the fastest CAGR of 14.7% from 2019 to 2026. The market also analyses regions including Europe, North America, and LAMEA.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/330

The conjugate segment to maintain its lead by 2026

Based on vaccine type, the conjugate segment held the largest share of the global meningococcal vaccine market, accounting for nearly half of the total market share in 2018, and is estimated to maintain its lead by 2026. Moreover, this segment is estimated to grow at the highest CAGR of 10.2% from 2019 to 2026. This is attributed to usage of vaccines in routine immunization schedules, preventive campaigns, and outbreak responses. The research also analyzes segments including polysachharide and subcapsular.

North America to maintain its dominance throughout the forecast period

Based on region, North America accounted for the largest market share in terms of revenue in 2018, holding nearly half of the global meningococcal vaccine market, and is estimated to maintain its lead position throughout the forecast period. This is due to surge in prevalence of meningitis disease and ease in availability of meningococcal vaccine products for treatment of the disease. However, Asia-Pacific is expected to portray the largest CAGR of 14.7% from 2019 to 2026, owing to surge in outbreaks of meningococcal diseases and widespread availability of products.

Leading market players:

Bio-Manguinhos
Bio-Med Pvt. Limited
Chongqing Zhifei Biological Products Co., Ltd.
GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Incepta Pharmaceuticals Ltd.
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Pvt. Ltd.
Walvax Biotechnology Co., Ltd.

Read More: https://www.alliedmarketresearch.com/meningococcal-vaccines-market

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.